<h2 dir="ltr">EGFR-NSCLC</h2>
EGFR is a protein in cells that helps them grow. A mutation in the EGFR gene can lead to excessive growth, potentially causing cancer. There are different types of EGFR mutations, including deletions or insertions and point mutations.&nbsp;
<h2 dir="ltr">Symptoms</h2>
<ul>
<li dir="ltr" role="presentation">A cough that does not go away or gets worse over time</li>
<li dir="ltr" role="presentation">Coughing up blood</li>
<li dir="ltr" role="presentation">Chest pain or discomfort</li>
<li dir="ltr" role="presentation">Trouble breathing</li>
<li dir="ltr" role="presentation">Wheezing</li>
<li dir="ltr" role="presentation">Hoarseness</li>
<li dir="ltr" role="presentation">Loss of appetite</li>
<li dir="ltr" role="presentation">Weight loss for no reason</li>
<li dir="ltr" style="font-weight: bold;" role="presentation"><a href="../report/update/659528e889fd1e9bb0c3ada1">Fatigue</a></li>
<li dir="ltr" role="presentation">Trouble swallowing</li>
<li dir="ltr" role="presentation">Swelling in the face and/or veins in the neck</li>
</ul>
<h2 dir="ltr">Diagnosis</h2>
<ul>
<li dir="ltr" role="presentation">Imaging tests (<a href="https://www.delveinsight.com/report-store/magnetic-resonance-imaging-devices-market">MRI</a>, <a href="https://www.delveinsight.com/report-store/computed-tomography-market">CT scan</a>, PET, etc.)</li>
<li dir="ltr" role="presentation">Bronchoscopic biopsy</li>
<li dir="ltr" role="presentation">Immunohistochemical staining</li>
<li dir="ltr" role="presentation">Thoracentesis</li>
<li dir="ltr" role="presentation">Sputum cytology</li>
<li dir="ltr" role="presentation">Biomarker testing</li>
</ul>
&ldquo;Most NSCLC cases are diagnosed at the metastatic stage (Stage IIIB-IV), accounting for nearly 50% of total cases, whereas only a minority are detected at earlier, surgically resectable stages. This late-stage predominance is largely due to delayed symptom onset and lack of effective screening, driving higher demand for systemic therapies.&rdquo;
<h2 dir="ltr">Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" role="presentation">Total Incident Cases of NSCLC&nbsp;</li>
<li dir="ltr" role="presentation">Gender-specific Cases of NSCLC</li>
<li dir="ltr" role="presentation">Age-specific Cases of NSCLC</li>
<li dir="ltr" role="presentation">Total Incident Cases of NSCLC by Histology</li>
<li dir="ltr" role="presentation">Total Incident Cases of NSCLC by Stage (at diagnosis)&nbsp;</li>
<li dir="ltr" role="presentation">Total Cases of EGFR-NSCLC&nbsp;</li>
<li dir="ltr" role="presentation">Treated Patient Pool Across the Lines of Therapies&nbsp;</li>
</ul>
<h2 dir="ltr">Epidemiology Insights&nbsp;</h2>
total incident population in the 7MM - 540K
US - 26%
EU4 and the UK - 27%
Japan - 47%
57% of cases were adenocarcinoma among histology-specific cases in the 7MM
EGFR Exon 19 deletions contributed to the highest number of cases, nearly 10,000 in the EGFR NSCLC in the US.
&ldquo;Males face a higher lifetime risk of developing lung cancer and experience greater mortality compared to females. This disparity is partly attributed to lifestyle factors, as men are more likely to engage in cigarette smoking, alcohol consumption, high-calorie diets, and drug use, all of which elevate lung cancer risk.&rdquo;
*these figures represent the 2025 data
<h2 dir="ltr">Approved Drugs</h2>
<ul>
<li dir="ltr" role="presentation">ZEGFROVY: Dizal Pharmaceutical</li>
<li dir="ltr" role="presentation">DATROWAY: Daiichi Sankyo/AstraZeneca</li>
<li dir="ltr" role="presentation">AUMSEQA: Jiangsu Hansoh Pharmaceutical</li>
<li dir="ltr" role="presentation">TAGRISSO: AstraZeneca</li>
<li dir="ltr" role="presentation">GILOTRIF/GIOTRIF: Boehringer Ingelheim</li>
<li dir="ltr" role="presentation">VIZIMPRO: Pfizer</li>
<li dir="ltr" role="presentation">RYBREVANT &plusmn; LAZCLUZE: Johnson &amp; Johnson Innovative Medicine/Yuhan Corporation</li>
<li dir="ltr" role="presentation">PORTRAZZA: Eli Lilly and Company</li>
</ul>
&ldquo;EGFR is one of the most clinically validated and commercially attractive NSCLC biomarkers, ensuring continued R&amp;D focus and strong investor interest. Its well-characterized mutation profile allows for precise drug development strategies and predictable market uptake.&rdquo;
&ldquo;Within EGFR-NSCLC, where osimertinib maintains market leadership, J&amp;J&rsquo;s amivantamab is steadily gaining ground. It has entered the broader first-line EGFR-mutated market through combination with the oral EGFR-Tyrosine Kinase Inhibitor lazertinib, and the company has launched a subcutaneous version of amivantamab + lazertinib in Europe, with a US launch expected soon. Given its expanding role and dual mechanism as an EGFR x cMET bispecific, amivantamab is well-positioned to evolve into a potential billion-dollar product.&rdquo;
<h2 dir="ltr">Market Insight&nbsp;</h2>
CAGR of 7.3% is predicted for the market during the forecast period (2026-2036)
market size in the 7MM in 2025 - USD 6.6 billion
55% of the total market share was accounted by the US
&ldquo;The market is expected to grow owing to the approval of new agents in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations.&rdquo;
&ldquo;There is no one-size-fits-all &ldquo;best&rdquo; treatment for EGFR NSCLC. Clinicians must be equipped with the appropriate tools to provide therapies with individual patient needs. In the first-line EGFR NSCLC segment, there are two excellent combination regimens (Chemo backbone FLAURA2 study and biologic innovation MARIPOSA study) which creates complementary treatment strategies.&rdquo;
In 2036, among all the therapies for EGFR NSCLC, the highest revenue is estimated to be generated by amivantamab (RYBREVANT) &plusmn; lazertinib (LAZCLUZE) followed by osimertinib (TAGRISSO), in the US.
The entry of late-stage candidates such as zipalertinib, furmonertinib is expected to intensify competition in the EGFR NSCLC treatment landscape during the latter forecast period.
<h2 dir="ltr">SWOT Analysis</h2>
<ul>
<li dir="ltr" aria-level="1">
Strengths
</li>
<ul>
<li dir="ltr" aria-level="2">
Premium pricing and label expansion into 1L metastatic NSCLC create strong revenue growth potential and a clear commercial advantage over chemotherapy-based approaches.
</li>
</ul>
<li dir="ltr" aria-level="1">
Weakness
</li>
<ul>
<li dir="ltr" aria-level="2">
Atypical EGFR mutations also remain underrepresented in clinical trials, and mutation-specific variability in drug sensitivity creates uncertainty in treatment selection.
</li>
</ul>
<li dir="ltr" aria-level="1">
Opportunities
</li>
<ul>
<li dir="ltr" aria-level="2">
Zipalertinib&rsquo;s best-in-class potential provides a unique chance to address substantial unmet needs in patients who have progressed on currently approved EGFR therapies. Its differentiated mechanism and efficacy could position it as a leading option in difficult-to-treat populations.&nbsp;
</li>
</ul>
<li dir="ltr" aria-level="1">
Threats
</li>
<ul>
<li dir="ltr" aria-level="2">
Pricing and affordability pressures may affect adoption in emerging markets. High-cost therapies could limit patient access, particularly in regions without robust reimbursement frameworks.
</li>
</ul>
</ul>
<h2 dir="ltr">Emerging Drugs</h2>
<div dir="ltr" align="left">
<table style="margin-left: auto; margin-right: auto;"><colgroup><col width="139"><col width="143"><col width="124"><col width="124"></colgroup>
<tbody>
<tr>
<td>
Drug Name
</td>
<td>
Company
</td>
<td>
MOA
</td>
<td>
ROA
</td>
</tr>
<tr>
<td>
Zipalertinib
</td>
<td>
Cullinan Oncology/ Taiho Pharma
</td>
<td>
Irreversible EGFR inhibitor
</td>
<td>
Oral
</td>
</tr>
<tr>
<td>
Firmonertinib
</td>
<td>
ArriVent BioPharma
</td>
<td>
EGFR inhibitor
</td>
<td>
Oral
</td>
</tr>
<tr>
<td>
Ivonescimab (SMT112)
</td>
<td>
Akeso Biopharma/Summit Therapeutics
</td>
<td>
PD-1/VEGF inhibitor
</td>
<td>
IV infusion
</td>
</tr>
<tr>
<td>
Sacituzumab Tirumotecan (MK-2870)
</td>
<td>
Merck/Kelun-Biotech
</td>
<td>
TROP2-directed ADC
</td>
<td>
IV infusion
</td>
</tr>
<tr>
<td>
Izalontamab Brengitecan (BMS-986507)
</td>
<td>
Bristol-Myers Squibb
</td>
<td>
Anti-EGFR and Anti-HER3
</td>
<td>
IV infusion
</td>
</tr>
</tbody>
</table>
</div>
<h2 dir="ltr">EGFR-NSCLC Market: Key Insights</h2>
total incident population in the 7MM in 2025 - 540K
market size in the 7MM in 2025 - USD 6.6 billion
Key Companies: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hansoh Pharmaceutical, Johnson &amp; Johnson Innovative Medicine, Pfizer, Cullinan Oncology, Taiho Pharmaceutical, ArriVent Biopharma, Black Diamond Therapeutics, Daiichi Sankyo, Akeso Biopharma, Summit Therapeutics
<h2 dir="ltr">EGFR-NSCLC Epidemiology Insights</h2>
total incident population in the 7MM - 540K
US - 26%
EU4 and the UK - 27%
Japan - 47%
57% of cases were adenocarcinoma among histology-specific cases in the 7MM
EGFR Exon 19 deletions contributed to the highest number of cases, nearly 10,000 in the EGFR NSCLC in the US.
&ldquo;Males face a higher lifetime risk of developing lung cancer and experience greater mortality compared to females. This disparity is partly attributed to lifestyle factors, as men are more likely to engage in cigarette smoking, alcohol consumption, high-calorie diets, and drug use, all of which elevate lung cancer risk.&rdquo;
*these figures represent the 2025 data
<h2 dir="ltr">EGFR-NSCLC Market Insight</h2>
CAGR of 7.3% is predicted for the market during the forecast period (2026-2036)
market size in the 7MM in 2025 - USD 6.6 billion
55% of the total market share was accounted by the US
&ldquo;The market is expected to grow owing to the approval of new agents in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations.&rdquo;
&ldquo;There is no one-size-fits-all &ldquo;best&rdquo; treatment for EGFR NSCLC. Clinicians must be equipped with the appropriate tools to provide therapies with individual patient needs. In the first-line EGFR NSCLC segment, there are two excellent combination regimens (Chemo backbone FLAURA2 study and biologic innovation MARIPOSA study) which creates complementary treatment strategies.&rdquo;
In 2036, among all the therapies for EGFR NSCLC, the highest revenue is estimated to be generated by amivantamab (RYBREVANT) &plusmn; lazertinib (LAZCLUZE) followed by osimertinib (TAGRISSO), in the US.
The entry of late-stage candidates such as zipalertinib, furmonertinib is expected to intensify competition in the EGFR NSCLC treatment landscape during the latter forecast period.

EGFR Non-Small Cell Lung Cancer (EGFR+ NSCLC) Market

EGFR Non-Small Cell Lung Cancer (EGFR+ NSCLC) Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.